Maternal uniparental disomy (UPD) 15 is one of the molecular causes of Prader-Willi syndrome (PWS), a multisystem disorder which presents with neonatal hypotonia and feeding difficulty. Current diagnostic algorithms differ regarding the use of SNP microarray to detect PWS. We retrospectively examined the frequency with which SNP microarray could identify regions of homozygosity (ROH) in patients with PWS. We determined that 7/12 (58%) patients with previously confirmed PWS by methylation analysis and microsatellite-positive UPD studies had ROH (>10 Mb) by SNP microarray. Additional assessment of 5,000 clinical microarrays, performed from 2013 to present, determined that only a single case of ROH for chromosome 15 was not caused by an imprinting disorder or identity by descent. We observed that ROH for chromosome 15 is rarely incidental and strongly associated with hypotonic infants having features of PWS. Although UPD microsatellite studies remain essential to definitively establish the presence of UPD, SNP microarray has important utility in the timely diagnostic algorithm for PWS.

Driscoll DJ, Miller JL, Schwartz S, Cassidy SB: Prader-Willi syndrome, in Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, et al (eds): GeneReviews® [Internet] (University of Washington, Seattle 1993-2017). Initial posting: October 6, 1998; last update: February 4, 2016.
Engel E: A new genetic concept: uniparental disomy and its potential effect, isodisomy. Am J Med Genet 6:137-143 (1980).
Fridman C, Koiffmann CP: Origin of uniparental disomy 15 in patients with Prader-Willi or Angelman syndrome. Am J Med Genet 94:249-253 (2000).
Izumi K, Santani AB, Deardorff MA, Feret HA, Tischler T, et al: Mosaic maternal uniparental disomy of chromosome 15 in Prader-Willi syndrome: utility of genome-wide SNP array. Am J Med Genet A 161A:166-171 (2013).
Keren B, Chantot-Bastaraud S, Brioude F, Mach C, Fonteneau E, et al: SNP arrays in Beckwith-Wiedemann syndrome: an improved diagnostic strategy. Eur J Med Genet 56:546-550 (2013).
Liehr T: Cytogenetic contribution to uniparental disomy (UPD). Mol Cytogenet 3:8 (2010).
McCandless SE; Committee on Genetics: Clinical report-health supervision for children with Prader-Willi syndrome. Pediatrics 127:195-204 (2011).
Milner KM, Craig EE, Thompson RJ, Veltman MW, Thomas NS, et al: Prader-Willi syndrome: intellectual abilities and behavioural features by genetic subtype. J Child Psychol Psychiatry 46:1089-1096 (2005).
Nicholls RD, Knoll JH, Butler MG, Karam S, Lalande M: Genetic imprinting suggested by maternal heterodisomy in nondeletion Prader-Willi syndrome. Nature 342:281-285 (1989).
Prasad AN, Prasad C: Genetic evaluation of the floppy infant. Semin Fetal Neonatal Med 16:99-108 (2011).
Tucker T, Schlade-Bartusiak K, Eydoux P, Nelson TN, Brown L: Uniparental disomy: can SNP array data be used for diagnosis? Genet Med (2012), E-pub ahead of print.
Varela MC, Kok F, Setian N, Kim CA, Koiffmann CP: Impact of molecular mechanisms, including deletion size, on Prader-Willi syndrome phenotype: study of 75 patients. Clin Genet 67:47-52 (2005).
Wang JC, Ross L, Mahon LW, Owen R, Hemmat M, et al: Regions of homozygosity identified by oligonucleotide SNP arrays: evaluating the incidence and clinical utility. Eur J Hum Genet 23:663-671 (2015).
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.